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Local priming of osteoclast precursors (OCp) has long been considered the main and
obvious pathway that takes place in the human body, where local bone lining cells
and RANKL-expressing osteocytes may facilitate the differentiation of OCp. However,
priming of OCp away from bone, such as in inflammatory tissues, as revealed in
peripheral blood, may represent a second pathway, particularly relevant in individuals
who suffer from systemic bone loss such as prevalent in inflammatory diseases. In
this review, we used a systematic approach to review the literature on osteoclast
formation in peripheral blood in patients with inflammatory diseases associated with
bone loss. Only studies that compared inflammatory (bone) disease with healthy controls
in the same study were included. Using this core collection, it becomes clear that
experimental osteoclastogenesis using peripheral blood from patients with bone loss
diseases in prevalent diseases such as rheumatoid arthritis, osteoporosis, periodontitis,
and cancer-related osteopenia unequivocally point toward an intrinsically increased
osteoclast formation and activation. In particular, such increased osteoclastogenesis
already takes place without the addition of the classical osteoclastogenesis cytokines
M-CSF and RANKL in vitro. We show that T-cells and monocytes as OCp are the
minimal demands for such unstimulated osteoclast formation. In search for common
and disease-specific denominators of the diseases with inflammation-driven bone loss,
we demonstrate that altered T-cell activity and a different composition—such as the
CD14+CD16+ vs. CD14+CD16– monocytes—and priming of OCp with increased
M-CSF, RANKL, and TNF- α levels in peripheral blood play a role in increased osteoclast
formation and activity. Future research will likely uncover the barcodes of the OCp in the
various inflammatory diseases associated with bone loss.
Keywords: peripheral blood, osteoclast formation, T-cells, CD14+CD16+, osteoclast precursor priming,
inflammatory bone diseases
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INTRODUCTION
Close inspection of skeletons as seen in anatomy museums
may show signs of inflammatory bone loss, present as joint
erosions and bone degradation of the tooth sockets that surround
teeth. This betrays an evoked activity of bone degradation
by inflammation steered osteoclasts, so different from turn-over
osteoclasts that in fact leave the rest of the skeleton seemingly
normal. The different bone cells, osteoclasts, bone-lining cells,
osteoblasts and osteocytes are responsible for a lifelong balanced
remodeling process. When this process becomes unbalanced,
such as during inflammatory diseases with bone-loss, it may
result in severe bone loss, locally, or systemically. The key
cell-type in this disturbed bone balance is the osteoclast,
the multinucleated cell responsible for breaking down bone
tissue (1).
Osteoclasts derive from cells of the monocyte/macrophage
lineage (2–4) present in bone marrow (5), but also present in
peripheral blood (6). Osteoclasts play a key role in diseases that
are associated with increased bone loss (7). Such diseases include
common diseases such as the rheumatic diseases, osteoporosis,
periodontitis, cancers that metastasize to bone and Crohn’s
disease. Less common diseases that also give rise to bone loss
are chronic liver disease, Gaucher’s disease, Turner’s syndrome,
and phenylketonuria. Bone loss is also frequently observed in
patients with chronic kidney disease. In nearly all of these
diseases, excessive osteoclast generation and activation, with a
key contribution to the altered immune system plays a dominant
role. All these diseases are discussed in detail below.
Growth factors and cytokines that can be produced by a
wide range of cells in the human body regulate the activity
and formation of osteoclasts. The principle differentiation
factors for osteoclast differentiation are macrophage colony-
stimulating factor (M-CSF), receptor activator of nuclear factor
kappa-B ligand (RANKL) (8) and the inhibitor of osteoclast
differentiation, the “protector of bone,” osteoprotegerin (OPG)
(9). These cytokines are produced by osteocytes and bone lining
cells/osteoblasts (10). However, RANKL can also be produced
by T-cells (11, 12), by synovial fibroblasts from inflamed joints
(13) and by tooth-associated fibroblasts (14). Apart from this
classical pathway, it was demonstrated by Kim et al. using
RANK-/- mouse models, that osteoclasts may also form through
stimulation with inflammatory cytokines such as tumor necrosis
factor-α (TNF-α) (15).
Apart from the common culture methods of osteoclasts using
M-CSF and RANKL, there are strong indications that osteoclast
precursors may differentiate into multinucleated osteoclasts in
the absence of added osteoclastogenesis stimulating factors M-
CSF and RANKL. This is referred to as “spontaneous” or
unstimulated osteoclast formation (16, 17), recently excellently
reviewed by Salamanna et al. (7). A better term for this could
be self-stimulatory osteoclastogenesis, where the combination
of T-cells that may provide the osteoclastogenesis signals with
primed OCp may give rise to osteoclast formation. Here,
and experimental evidence is provided below, cells from
peripheral blood, such as T-cells, may provide the necessary
differentiation factors for the monocytic, CD14+ osteoclast
precursor cells in blood. These studies are based on experimental
in vitro studies which suggest an activation of the OCp by
inflammatory mediators present in the plasma of patients with
inflammatory bone disease or an intrinsic change of cells toward
more osteoclastic differentiation. Examples include periodontitis,
osteoporosis, Crohn’s disease, rheumatoid arthritis, and bone
metastatic cancer and will be further described later on in
this review.
The aim of this systematic literature review is to provide an
overview and an interpretation of experimental in vitro studies
involving osteoclast formation from peripheral blood of patients
with inflammatory diseases that lead to bone loss compared to the
osteoclast formation from peripheral blood of healthy controls.
This will gain insight into the various mechanisms that play a
role in the activation of osteoclasts from peripheral blood in these
inflammatory bone diseases. The similarities and differences
in peripheral blood-mediated osteoclast formation between the
various inflammatory diseases associated with bone loss will be
examined and discussed.
LITERATURE SEARCH
Themethodological approach of systematic review was used. The
PRISMA (Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) was used to reduce the bias in the selection of




#2 Osteoclast OR osteoclasts
#3 Osteoclast formation OR osteoclast differentiation
OR osteoclastogenesis
#4 (Periodontitis OR periodontal disease) OR rheumatoid
arthritis OR psoriatic arthritis OR inflammatory bowel
disease OR Crohn’s disease OR osteoporosis OR bone
metastatic cancer
#5 (#1 AND #2 AND #3 AND #4) AND
(“2002/01/01”[PDat]: “2018/07/31”[PDat])
The electronic search for relevant studies was carried out
in the three databases Pubmed, Embase, and Web of
science. The keywords used for the search were “peripheral
blood,” “osteoclast,” “osteoclasts,” “osteoclast formation,”
“osteoclast differentiation,” “osteoclastogenesis,” “periodontitis,”
“periodontal disease,” “rheumatoid arthritis,” “psoriatic arthritis,”
“inflammatory bowel disease,” “Crohn’s disease,” “osteoporosis,”
“bone metastatic cancer.” In terms of time and language,
articles published from 2002 until 2018 were assessed and only
publications in English were included in this study.
SCREENING AND SELECTION
A set of inclusion and exclusion criteria were used to retrieve
relevant in vitro studies. All in vitro studies involving exogenously
added cytokine driven and spontaneous osteoclast formation
from peripheral blood from patients with periodontitis or
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rheumatoid arthritis or psoriatic arthritis or osteoporosis or
Crohn’s disease or bone metastatic cancer were included for
further examination.
The titles and abstracts of all publications identified by the
electronic search were manually screened and discussed by two
reviewers (IB and TdV). When the suitability of an article for
this review could not be determined based on the title and
abstract, the full text was read and examined by one reviewer
(IB) and reported and discussed (IB and TdV). Outcomes of in
vitro studies included comparison between osteoclast formation
from peripheral blood of patients with one of the diseases listed
above and healthy controls. All articles that did not meet with the
primary outcome of interest, (spontaneous) osteoclast formation
from PBMCs or monocytes of diseased patients compared to
healthy controls were excluded, leaving 29 papers in the core-
collection (Figure 1).
Apart from the systematic approach on the common diseases
osteoporosis, periodontitis and rheumatoid arthritis, literature
on less frequent diseases (Turner, Gaucher, chronic liver disease,
Crohn’s disease, and phenylketonuria) that was found with this
search strategy was incorporated.
PERIPHERAL BLOOD OSTEOCLAST
FORMATION IS INCREASED IN A WIDE
SPECTRUM OF BONE DISEASES
Overall it can be concluded that osteoclast formation from
peripheral blood cells is increased in a wide range of diseases




Rheumatoid arthritis is a chronic inflammatory joint disease that
is characterized by chronic synovitis and exaggerated local and
systemic bone loss. It was established by Gravallese et al., that
osteoclasts accumulate in the joints of RA patients (44) and
that RANKL, the key osteoclastogenic mediator, is expressed
locally in the joints of RA patients (45). Systemically, increased
circulating osteoclast precursors have been reported in RA, which
express key osteoclastogenic molecules on their surface (46, 47).
Notably, when exposing similar numbers of peripheral CD14+
cells to osteoclastogenic conditions, more osteoclasts form in
RA patients than in healthy controls (20), which is a strong
argument that these peripheral osteoclast precursors are primed
in the circulation. Moreover, elevated osteoclast formation in
RA was shown to be correlated to local and systemic bone
loss in RA (23). In addition, data showed that RA affects the
longevity of osteoclasts, with a significantly lower number of
osteoclasts undergoing apoptosis in RA compared to the healthy
controls (22).
Enhanced osteoclastogenesis in RA essentially depends on
T cells (48). Thus, in T-cell (CD3+ cells) depleted cultures,
osteoclast precursors from RA patients show significantly lower
spontaneous differentiation. Addition of exogenous RANKL to
these cultures resulted in partial recovery of osteoclast formation.
Together, these data indicate a crucial role for T-cells in osteoclast
formation in RA, in line with earlier studies that demonstrated
the activating role of T-cells in osteoclast formation (8, 49) which
initiated osteoimmunology research. Miranda-Carus et al. (21)
showed that T-cells present in peripheral blood play a major
role in the formation of osteoclasts in RA patients. They interact
with the osteoclast precursors of the monocyte/ macrophage
lineage in vitro. An increased level of TNF-α, IL-1, IL-17, and
RANKL was also found in the autologous T-cell/monocyte co-
cultures derived from patients with early RA and established RA
compared with controls (21) suggesting that these cytokines drive
osteoclast differentiation in RA. Especially CD4+ T-cells play a
role in osteoclastogenesis. OPG, anti-TNF-α and anti-IL-1 in this
study, were shown to inhibit osteoclast formation (21).
Psoriatic Arthritis
Psoriatic arthritis (PsA) is a chronic inflammatory joint disease,
which develops in about 30% of patients with psoriasis and is
characterized by local bone erosions and systemic bone loss.
TNFa and the interleukins 17 and −23 are key mediators of
bone loss in PsA (50). In 2003, Ritchlin et al. (18) showed
that the number of osteoclast precursors is increased in patients
with PsA. In part, the development of osteoclasts in PsA
could be independent from M-CSF or RANKL. This could be
explained by a higher number of circulating OC precursors or
by the ability of maturation of osteoclast precursors without
supplementation with exogenous levels of M-CSF or RANKL.
Ritchlin et al., also showed strong RANKL expression in synovial
tissue of PsA patients as well as strong RANK expression
in osteoclasts at areas with bone erosion. Fewer osteoclasts
formed from blood of PsA patients after anti-tumor necrosis
factor-α (TNF-α) treatment, indicating that TNF-α primes OC
precursors in PsA (16). The original findings of Ritchlin et al.,
were also corroborated by Colucci et al., who showed that
more TRAP+ multinucleated cells formed in cultures from
PsA patients. Interestingly, supplementation of inflammatory
cytokines abrogated these differences between PsA patients
and controls (Table 1). This finding indicates an intrinsically
higher osteoclastogenesis potential of blood from PsA patients.
Increased osteoclast formation in PBMCs appears to be T-cell
dependent, since the formation of osteoclasts was absent in
T-cell-depleted PBMC cultures, which implies that T-cells are
responsible for osteoclast formation. These results also suggest
that blockade of RANKL and TNF-α might be used as an
effective strategy for inhibiting enhanced osteoclastogenesis in
PsA patients (19). Indeed such concept is supported by data
on TNF inhibitors, which effectively inhibit osteoclast formation
(51). Notably, aside from inflammation, PsA is strongly linked
to obesity and the metabolic syndrome. In this context it is
interesting that Xue et al., found an elevated value of certain
adipokines, cytokines derived from adipose tissues, in the
circulation of patients with PsA (52). Adipokines like leptin,
adiponectin, chemerin, and omentin may not only play a role
in inflammation but also in osteoclastogenesis in patients with
PsA. Higher levels of leptin and omentin, for instance, positively
correlated with the number of osteoclast precursors found in
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FIGURE 1 | Flow chart of the literature search strategy.
PsA patients, while adiponectin was negatively correlated with
osteoclast precursors.
Osteoarthritis
In osteoarthritis (OA) (24), the key degenerative joint disease,
it was found that the number of TRACP+ multinucleated
osteoclasts is higher than in healthy controls providing an
explanation for the sometimes bone erosive phenotype of OA.
No significant difference was found between OA and healthy
controls regarding the number of circulating CD14+ cells.
However, osteoclasts from the OA patients were found capable of
resorbing a significantly larger (4 times) area than the osteoclasts
from the healthy controls. The higher number of osteoclast-
like cells formed by the PBMCs from the osteoarthritis group
compared to the PBMCs from the control group could be
responsible for enhanced local bone resorption in OA.
Though strictly speaking not a rheumatoid disease, Charcot’s
arthropathy that is associated with diabetes co-incides with joint
erosions, in particular of the foot (53). Charcot’s arthropathy is
associated with increased peripheral blood osteoclast formation,
with more osteoclasts than in matched diabetes patients without
Charcot’s arthropathy is or healthy controls (26). A later study
from the same group showed that higher numbers of CD14+ cells
prevail in blood of patients with Charcot foot, concomitant with
higher peripheral blood TNF-α levels (53).
Acroosteolysis
Also patients suffering from acroosteolysis, which is part
of the systemic sclerosis disease spectrum, show increased
osteoclast formation compared to healthy controls. In this
context, the increased osteoclast formation is associated
with higher VEGF levels in the peripheral blood (27).
VEGF can substitute for M-CSF in driving osteoclast
differentiation (54).
Ankylosing Spondylitis
Ankylosing spondylitis is an inflammatory rheumatic disease
of the spine, which is characterized by loss of trabecular bone
but periosteal apposition of cortical bone leading to bony
spur formation sometimes leading to fusion of vertebra (55).
Interestingly, ankylosing spondylitis is the only rheumatic disease
where data showed that less osteoclasts form in vitro and
where data on serum CTX levels show that lower overall
bone resorption happens. Lower osteoclast numbers correlated
with lower RANKL/OPG ratios. Furthermore, osteoclasts from
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Disease, study Disease Healthy control Resorption? Disease Healthy control Resorption?
REUMATOID DISEASES
PsA, Ritchlin et al. (18) 168 3.7* D>C N.D. N.D. D>C
PsA, Colocci et al. (19) 49 0 [n.t.]* D>C 55 50 [n.t.] N.D.
PsA, Ikic et al. (20) N.D. N.D. N.D. 120 40* N.D.
RA, Miranda-Carus et al. (21) 100 5* D>C N.D. N.D. N.D.
RA and OA, Durand et al. (22) N.D. N.D. N.D. 450* 350 N.S
RA, Ikic et al. (20) N.D. N.D. N.D. 360* 40 N.D.
RA, Shang et al. (23) N.D. N.D. N.D. 125* 75 N.S.
OA, Durand et al. (24) N.D. N.D. N.D. 248* 210 D>C
AS, Caparbo et al. (25) N.D. N.D. N.D. 700 750*
Charcot’s osteoarthropathy, Mabilleau et al. (26) N.D. N.D. N.D. 96* 56 (diabetes) 21 (HC) D>C
Acroosteolysis, Park et al. (27) ND ND ND 142 18* D>C
OSTEOPOROSIS
Jevon et al. (28) 9 7 D>C ND ND ND
D’Amelio et al. (17) 48 15* D>C 50 40 N.D.
D’Amelio et al. (29) 145 5* D>C 180 140 N.D.
Koek et al. (30) N.D. N.D. N.D. 28 27 N.S.
PERIODONTITIS
Brunetti et al. (12) 59 5* D>C 70 62 N.D.
Tjoa et al. (31) 14 8 N.D. 14 15
Herrera et al. (32) 17 8* D>C ns ns N.S.
CANCER
Solid tumors, Roato et al. (33) 172 48* D>C 161 132 [n.s.] N.S.
Solid tumors, Roato et al. (34) 60 20*
Prostate cancer, Roato et al. (35) 216 73* N.D. N.D. N.D. N.D.
Gastric, D’Amico et al. (36) N.D. N.D. N.D. 90 40 N.S.
CHRONIC LIVER DISEASE
Olivier et al. (37) 35 20* 45 37 D>C
CROHN’S DISEASE
Oostlander et al. (38) 380 50* 0 ND ND
CHRONIC KIDNEY DISEASE
Cafiero et al. (39) 20 1* D>C ±40 40 N.D.
TURNER’S SYNDROME
Faienza et al. (40) 49 5* D>C ±42 ±50 N.D.
GAUCHER
Mucci et al. (41) N.D. N.D. N.D. ±140 ±75* D>C
Reed et al. (42) N.D. N.D. N.D. ±120 ±40* D>C
PHENYLKETONURIA
Roato et al. (43) 149 91* D>C 189 124* ND
N.D., not determined; *, significantly different from disease; N.N., not significantly different from disease; D, Disease; C, control. Numbers of osteoclasts formed between studies are
not comparable, since culture conditions differed between the studies.
ankylosing spondylitits patients were less prone to apoptosis (25)
which has also been observed in other rheumatic diseases (24).
Osteoporosis
Osteoporosis is a skeletal disease characterized by lower bone
mass and micro-architectural deterioration of bone leading to an
increased risk of fractures (56). Several indications show that this
phenomenon is caused by a higher activity of osteoclasts due to
an imbalance of the osteoclasts and osteoblasts, postmenopausal
bone loss is triggered by estrogen deficiency that increased
osteoclastogenesis through several pathways, and in particular
by the activation of T cells that produce higher level of pro-
inflammatory and pro-osteoclastogenic cytokines as TNFα and
RANKL (57). Bone fractures are the severe consequence of
osteoporosis and represent a major health problem in the
increasingly older (58). Old patients experiencing a femoral
fracture have a decreased life expectancy and may become
care-dependent in half the survivors. The presence of a fragility
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fracture increases the risk of new fractures creating a “domino
effect”: one vertebral fracture doubles the risk of subsequent
femoral fracture within a year, the presence of vertebral fractures
as well as of femoral fracture impair patients’ quality of life and
increase mortality.
In a first study comparing the peripheral blood osteoclast
formation from patients and controls, similar numbers of
osteoclasts formed, but the resorptive capacity was higher in
osteoclasts from osteoporosis patients (28), suggesting that the
peripheral OCp had the same osteoclastogenic potential, but
were somehow primed to form more active osteoclasts (28).
D’Amelio et al. (17, 57) investigated the osteoclast formation in
osteoporosis. The first study compared the osteoclast formation
in osteoporotic women compared to healthy controls, without
adding M-CSF, TNF-α, or RANKL to the cultures (17). A
higher number of osteoclasts was formed in the cultures
from osteoporosis blood compared to healthy controls. After
supplementation of M-CSF and RANKL the numbers of
osteoclasts reached a same level in controls and patients. A
significantly higher level of TNF-α and RANKL was found in
the PBMC cultures of the osteoporotic group. Adding 1,25-OH
vitamin D3 to the PBMCs cultures resulted in both groups in
lower numbers of osteoclasts, but higher resorption. The lacunar
resorption area was significantly higher in the osteoporotic
patients group compared to the healthy subjects with and
without the addition of 1,25-OH vitamin D3. Comparable results
were reported in the second paper by the same group (29):
higher levels of TNF-α and RANKL in the PBMC cultures
and higher osteoclast formation in the osteoporotic group
compared to the healthy subjects. Antibodies against TNF-
α and RANKL decreased spontaneous osteoclast formation
strongest in the osteoporotic group. Additionally this study
demonstrated that the T-cells of osteoporosis patients play a
key role in the osteoclastogenesis by increasing the TNF-α and
RANKL production. It was shown that osteoclast formation
was severely suppressed when depleting the T-cells from the
PBMCs cultures. This indicates that T-cells play a crucial role
in osteoclast formation and that they secrete cytokines necessary
for osteoclast formation in osteoporosis. In a fourth study, no
differences in osteoclast formation were found between controls
and osteoporotic patients (30), but in this case only M-CSF
and RANKL stimulated cultures were studied. This was in line
with the previous studies (17, 28, 57) regarding the stimulated
osteoclastogenesis, where addition of M-CSF and RANKL may
shield possible differences.
Periodontitis
Periodontitis is the inflammatory bone-destructive disease
affecting the alveolar bone between teeth. It’s individual
susceptibility is driven by an oral bacterial dysbiosis, genetic
factors (59) and life style (60). Currently, it is estimated that no
<46% of Americans adults have moderate to severe periodontitis
(61). When peripheral blood mononuclear cells (PBMC) from
chronic periodontitis patients were cultured in the absence of M-
CSF and RANKL, more osteoclast-like cells form from chronic
periodontitis patients (12). Osteoclast-like cells in the control
group were fewer and smaller. The addition of stimulating
factors M-CSF and RANKL resulted in comparable numbers
of osteoclast-like cells in control and periodontitis group. M-
CSF and RANKL only triggered osteoclast formation in the
control group, osteoclast numbers of the periodontitis group did
not increase after cytokine treatment. The osteoclasts formed
spontaneously from the PBMC cultures from the periodontitis
patients and showed a significantly higher resorbtive activity
compared to the controls. A T-cell dependent osteoclastogenesis
was shown in this study, since the number of osteoclasts
was low in the T-cell depleted unstimulated PBMCs cultures
from the periodontitis patients. Addition of stimulating factors
M-CSF and RANKL to these cultures led to a significantly
higher formation of numerous large osteoclasts. An explanation
for this finding is the overexpression of RANKL and TNF-
α by T-cells, which was shown to be higher by the T-cells
from the patient group. Addition of anti-RANKL and anti-
TNF-α antibodies induced a dose dependent inhibition of
the osteoclast formation in the periodontitis group (12). Also
Tjoa et al., aimed to determine if there was a difference in
osteoclast formation between the PBMC from patients suffering
from chronic periodontitis and matched healthy controls (31).
In this study, no differences were observed in unstimulated
osteoclast formation between controls and periodontitis patients.
A significant difference was shown however after the stimulation
with M-CSF between control and diseased group. Larger and
more multinucleated cells were found in the control group,
whereas the patient group was insensitive to stimulation with M-
CSF (31), suggesting that the OCp in this group were already
primed in the circulation. In another study, it was shown
that peripheral blood monocytes from periodontitis patients
are more prone to differentiate into mature multinucleated
osteoclasts (32). In other words, this study shows that these
monocytes were primed in peripheral blood and prepared here
for enhanced osteoclast formation. Only the stimulation with
RANKL and not with M-CSF and RANKL gave significant
differences between the periodontitis group and healthy controls
regarding the osteoclast-like cells formed. A significantly higher
level of M-CSF was found in the periodontitis group (32).
This could be an explanation for the insensitive response of
PBMC from periodontitis patients to stimulation with M-CSF
in the study of Tjoa et al. (31), since the osteoclast precursors
could be already pre-activated by higher M-CSF levels present
in serum.
Cancer That Metastasizes to Bone
Hematological Cancers
B cell multiple myeloma was studied by Colucci et al. who
cultured 10 times more osteoclasts in the absence of added
cytokines from myeloma blood than from control blood. As
described repetitively above, this difference was no longer
seen when the M-CSF and RANKL was added to these
cultures. Colluci et al., found that peripheral blood contained
upregulated OPG and RANKL levels. OPG co-precipitated with
TRAIL, by which more RANKL became available. Autologous
T-cells added to these osteoclasts, prolonged survival of
osteoclasts (11).
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Solid Tumor
Using blood from patients with bone metastasis from diverse
primary tumors such as melanoma, lung, prostate, kidney,
breast, and colon, it was found that these cultures gave rise
to more osteoclast compared to controls when no cytokines
were added (33). Addition of M-CSF and RANKL nullified
this effect. OCp from tumor patients were further characterized
and apart from CD14 and CD11, these precursors, and not
in the control group, also expressed the osteoclast marker the
vitronectin receptor αvβ3, which could be typical for precursors
that are a bit further differentiated, indicating that the OCp in
peripheral blood of cancer patients are already a step further in
differentiation. Addition of OPG did not inhibit unstimulated
osteoclast formation (33). It was shown that anti-TNF blocked
osteoclast formation (33), which was recently confirmed in
a separate study (51) Only T-cells from osteolysis patients
expressed TNF-α, and also osteoclasts derived from cancer
patients expressed TNF-α (33). The same group showed in
subsequent years with a relatively large cohort of heterogeneous
tumors (34) and in a group of prostate cancer (35) that most
osteoclasts are formed without stimulation in patients with bone
metastasis, compared to cancer patients without metastasis, and
least osteoclasts formed from blood from controls. In both
studies, a role of IL-7 was described. IL-7 serum levels were high
in patients with metastasis, lower in sera from patients without
and lower in control sera. T-lymphocytes could be identified
as the source for IL-7, antibodies against IL-7 significantly
inhibited osteoclast formation (34, 35). In a group of gastric
cancer patients, no differences were observed in numbers of
osteoclasts that differentiation from blood from patients with
metastases, from patients without metastases and controls (36).
An important difference with the other solid tumor studies was
that only cytokine stimulated conditions were considered.
Rarer Bone Diseases Associated With
Increased Bone Loss
Diseases Associated With Osteopenia: Chronic Liver
Disease, Crohn’s Disease and Chronic Kidney
Disease
Chronic liver disease can lead to osteoporosis, but not in all
individuals with chronic liver disease. In attempt to explain this
phenomenon, osteoclasts were cultured from blood of chronic
liver disease patients with osteopenia, without osteopenia and
matched healthy controls. More osteoclasts formed without
adding osteoclastic cytokines M-CSF and RANKL from blood
of osteopenic patients compared to non-osteopenic and healthy
controls (37). Interestingly, and in line with what was found in
the periodontitis study from the same group (31), only controls
responded with higher osteoclast numbers when stimulated
with M-CSF, whereas both osteopenic and non-osteopenic
patients did not respond to addition of M-CSF. Serum levels
M-CSF of both patient groups were significantly higher than
controls, suggesting M-CSF priming of OCp in peripheral blood.
Furthermore, number of osteoclasts cultured in vitro, correlated
negatively with the lumbar spine density score (37).
Though Crohn’s disease is an intestinal disease, it is associated
with inflammatory flair-ups periods. Some of the patients develop
osteoporosis, including those who are not on high levels of
corticosteroids. In a study with patients in a quiescent disease
stage, Oostlander et al. (38) were the first to describe the pre-
stages of unstimulated osteoclast formation. It was shown that
the formation of osteoclasts is preceded with a stage of cell
clusters, the number of which correlate with the numbers of
osteoclasts that form (38). In a similar approach as in a previous
study (57), OCp were either cultured with purified autologous
B-cells, T-cells or the combination or without. Osteoclasts only
formed in combinations where T-cells were present, which also
made part of the cell clusters that preceded osteoclast formation.
More osteoclasts formed from OCp:T-cell cultures from Crohn’s
disease than from controls and correlated to IL-17 levels in vitro.
TNF-α levels were highest in OCp+ T-cells, compared to T-cells
alone (no secretion) or monocytes only (lower levels), indicating
that the T-cell:OCp interaction induces TNF-expression (36),
later confirmed by Moonen et al. (3). Interestingly, the diverse
combinations of T-cells, B-cells, or T-Cells+ B-cells did not affect
control monocytes, indicating that the osteoclastogenesis driving
T-cell activity is increased in Crohn’s disease.
Bone disease in patients with chronic kidney disease (CKD) is
a major clinical concern due to its prevalence and consequences
that greatly impact patients quality of life (62). CKD patients
may be affected by both higher and lower bone turnover
disease, in patients with high bone turnover disease increased
osteoclastogenesis is sustained by both increased in inflammatory
and pro-osteoclastogenic cytokines and by increased PTH due
to the decreased ability of kidney to hydroxylate vitamin D
into its active form 1,25OHvitamin D. Patients with terminal
kidney failure who are on dialysis, experience a chronically
inflammatory state with often skeletal complications. Osteoclast
formation was studied both without and cytokine stimulation
(39). Osteoclast formation was lowest in controls, and higher
in early chronic patients and higher in late chronic patients
and highest in hemodialysis patients, similar correlations were
seen with resorptive capacity. RANKL was expressed on T-
lymphocytes in renal patients, not in controls. RANK-Fc can
inactive RANKL, and when added it dose dependently decreased
osteoclastogenesis, demonstrating that osteoclast formation was
RANKL dependent (39).
Rare Diseases Associated With Bone Loss: Turner’s
Syndrome, Gaucher’s Disease and Phenylketonuria
Patients with Turner’s syndrome may present with decreased
bone due to hypergonadism associated with the disease.
Estrogen deficiency could be the course for such bone loss (40).
Unstimulated osteoclast formation resulted in more osteoclasts
that were more active, both in the group with high levels
of follicle stimulating hormone (FSH) and with low levels.
These osteoclasts resorbed more calcium phosphate. Osteoclast
numbers from monocytes with addition of M-CSF and RANKL
were similar between controls and patients. The increased
unstimulated osteoclast formation in Turner’s syndrome
correlated with a lower percentage of osteoclastogenesis
inhibitory CD4+CD25+ cells and a higher percentage of CD3+
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NKT cells. The CD8+TNF-α+ cells were higher in Turner’s
syndrome, as well as the CD14+TNF-α+ monocytes. This
skewness could contribute and be responsible for the increased
osteoclast formation (40).
Gaucher’s disease is a heritable disease with deficiency of
the lysomal enzyme glucocerebrosidase, resulting in excess of
glycosylceramide, which is then stored in high quantities in
macrophages, concomitant with a disturbed immunological
balance and cytokine secretion profiles (42). Approximately 3-
fold more osteoclasts formed from Gaucher patient’s PBMC
cultured with M-CSF and RANKL. These osteoclasts were larger
in size and number of nuclei and resorbed larger areas of
bone. When distinguishing between active and non- active bone
disease, the Gaucher patients with active bone disease formed
more osteoclasts. Especially the Gaucher cultures were relatively
independent of M-CSF (42), in line with data from periodontitis
(31) and chronic liver disease patients (37). When control
PBMC were cultured with inhibitors of glucocerebrosidase,
increased numbers of osteoclast formed (42), indicating that
this enzyme plays a key role in tempering osteoclast numbers.
The increased osteoclast formation in Gaucher’s disease was
confirmed by Mucci et al. (41). Here, it was shown that
Gaucher’s disease blood contained a higher percentage of
non-classical/inflammatory CD14+CD16+ cells compared to
the classical CD14+CD16– monocytes. When culturing with
an enzyme that replenishes the missing glucocerebrosidase,
osteoclast numbers decreased only in Gaucher patients cultures,
again indicating that glucocerebrosidase tempers osteoclast
formation. T-cells from Gaucher’s disease express more RANKL
(41). Osteoclast cultures from controls were insensitive to OPG
or anti-TNF-α treatment, whereas osteoclast numbers went
significantly down in Gaucher’s PBMC cultures that were treated
with OPG or anti-TNF-α (41).
Phenylketonuria (PKU) is a rare, inherited disease with
a defect in the synthesis of the amino acid phenylalanine.
These patients have a hitherto not understood progressive
bone impairment. Also with this disease, increased osteoclasts
were cultured both without osteoclastogenesis stimulating
cytokines and with these cytokines (43). As shown for Gaucher
(41), the blood of PKU also contains a higher proportion
of CD14+CD16+ monocytes, which co-express CD51/CD61,
or αvβ3 integrin, that is typical for osteoclasts (63). The
unstimulated osteoclastogenesis cultures contained increased
levels of TNF-α and RANKL in PKU patients. Only RANK-
Fc, that blocks RANKL activity, decreased osteoclast numbers
in PKU cultures. PKU patients contained activated T- cells of
the CD4+CD25+CD69+ signature, a cell type that was absent
in controls.
GENERAL OSTEOCLASTOGENESIS
FEATURES OF INFLAMMATORY BONE
DISEASES
When summarizing the osteoclastogenesis capacity of the various
inflammatory bone disease, several features become apparent
(Table 1). Firstly, when taking together all 29 summarized
studies, more osteoclasts formed, be it unstimulated or stimulated
with M-CSF and RANKL. This was the case for 24 of the
29 studies. Secondly, in all cases where resorptive activity was
determined, the osteoclasts from bone loss diseases were more
active. Thirdly, osteoclasts can be cultured without exogenous
addition of M-CSF and RANKL, only when cultured from
PBMC or at least the addition of T-cells to OCp. These
osteoclasts often displayed lytic activity of calcium phosphate
coatings, but also bone resorption activity has been reported.
Fourthly, those studies that have compared unstimulated and
M-CSF and RANKL stimulated osteoclast formation, often
found increased osteoclast formation in unstimulated cultures,
whereas these differences were often not found any more
when cultured with M-CSF and RANKL. This accounted for a
variety of diseases, such as psoriatic arthritis (19), osteoporosis
(17, 57), periodontitis (12, 31), multiple myeloma (11), solid
tumors (33), chronic liver disease (37), kidney disease (39),
and Turner’s syndrome (40). This suggests that stimulation
with unphysiological levels of M-CSF and RANKL may hide
the intrinsically increased osteoclastogenic activities present in
peripheral blood. Especially these studies with self-stimulatory
osteoclastogenesis cocktails of T-cells and OCp can give us
clues of common and disease specific determinants of increased
osteoclast formation. Below, three common denominators which
stood out when comparing the various inflammatory bone
diseases, being (1) inflammatory mediators in serum, (2) the role
of T-cells and (3) differential priming or skewness in monocyte
distribution are worked out for the inflammatory bone diseases.
Common Inflammatory Mediators in
Serum Prepares OCp in the Circulation
A different priming whilst in the circulation by increased
levels of pro-osteoclastogenic mediators could make monocytes
more equipped to differentiate into osteoclasts. Most commonly
described is the increased presence of TNF-α, see the above
paragraph where it’s presence is discussed in the context of T-
cells, but also in serum from patients with Charcot’s disease,
where it co-incides with increased numbers of CD14+ cells (53).
Another such pro-osteoclastogenic cytokine is M-CSF. Higher
levels of M-CSF in the circulation have been described for
periodontitis (32) and chronic liver disease (37). This could
make PBMC from these patients less responsive to exogenous
M-CSF (31, 37).
A Common Role for T-Cells in Osteoclast
Formation in the Various Inflammatory
Bone Diseases
The general role of T- cells in osteoclast regulation (64),
the role of osteoclast activating T-cells such as Th17 (65)
and the regulatory role of Treggs (66) have been reviewed
elsewhere. Here, we describe the T-cell findings in the context
of inflammatory diseases with bone loss in the context of
the core collection used for this review. When reviewing the
above literature it is clear that T-cells are indispensable for
spontaneous osteoclastogenesis: without T-cells, no osteoclasts
form. This has been investigated for psoriatic arthritis (19, 48),
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osteoporosis (57), periodontitis (12) and Crohn’s disease (38).
Themechanism by which they adhere and stimulate OCp is likely
by LFA-1: ICAM-1 interaction, since antibodies against LFA-1
interfere both with cell cluster formation and with osteoclast
formation (38). TNF-α is most commonly reported as the
cytokine secreted by T-cells in the various diseases. T-cells from
patients with inflammatory bone loss diseases secrete more
TNF-α, as shown for psoriatic arthritis (19), osteoporosis (57),
periodontitis (12), and Turner’s syndrome (40). Exclusively the
T-cells from peripheral blood from patients with osteolytic solid
tumors and not those without osteolytic tumors were reported to
express detectable levels of TNF-α (34). Treating unstimulated
osteoclastogenesis cultures with anti TNF-α agent infliximab
reduces both cell cluster formation and osteoclast formation (51).
Anti-TNF-α treatment also decreased osteoclast formation in
patients with RA (18), periodontitis (12), and Gaucher’s disease
(41). T-cells from inflammatory bone diseases express more
RANKL, as reported for RA (21), osteoporosis (57), and chronic
kidney disease (39). Anti RANKL reduced osteoclast formation
in Gaucher’s disease more than in controls (41), and also
in phenylketonuria patients (43), chronic kidney disease (39).
Studies with RANKL-independent osteoclast formation were also
reported (33, 37). In these studies, OPG or RANK-Fc did not
affect osteoclast formation. Two osteoclastogenesis studies from
solid tumors report spontaneous osteoclastogenesis stimulated
by T-cell secreted IL-7 (34, 35). This has not been studied in
the other inflammatory bone loss diseases. Finally, it has been
reported for myeloma derived osteoclasts that autologous T-cells
added to osteoclast cultures may prolong osteoclast survival (11).
A Different Distribution of Monocytes
Subtypes and Different Monocyte Priming
in Inflammatory Diseases
A third commonality between the different diseases is that due
to the inflammatory disease, a skewed distribution of monocytes
that is better equipped to differentiate into osteoclasts populate
the peripheral blood. The existence of different monocyte
populations (2, 67) which distributions are then different between
disease and controls, is indeed a very attractive explanation
for the outcome of more osteoclasts in inflammatory disease.
One way to achieve a relatively crude and likely heterogeneous
populations of OCp is with CD14+ positive isolation. Studies
that show more osteoclasts as outcome, where equal numbers
of purified CD14+ monocytes were uses in disease vs. healthy
controls, provide a first indication for a better equipment of
these cells for osteoclast differentiation. This has been shown for
RA and psoriatic arthritis (20) and for periodontitis (32). When
comparing monocyte heterogeneity, two different criteria have
been used in the articles assessed in this review: an approach
based on CD14, CD11b, and the vitronectin receptor (VNR)
expression and themore commonly used CD14/CD16 expression
of monocytes. One study that has used CD14+ in conjunction
with CD11b and the vitronectin receptor or αvβ3 showed that
peripheral blood of osteolytic cancers contained more VNR+
monocytes, which correlated to higher osteoclast formation (33).
The muchmore commonly used classification of monocytes is
based on their CD14 and CD16 expression. The CD14+CD16–
are the classical monocytes that become the phagocytic cells
in tissues and comprise the majority of blood monocytes,
intermediate monocytes are CD14+CD16+ and are pro-
inflammatory and play a role in wound healing, and the
CD14+CD16++ cells are the non-classical monocytes that play a
role in patrolling and fibrosis (2, 67). Initial description on either
CD16– and CD16+, before the subsequent refinement of CD16+
monocytes into intermediate and non-classical monocytes (68)
and also recent literature on the transcriptome of the classical
and non-classical monocytes (69) suggest that the physiological
osteoclasts derive from classical, CD14+CD16– monocytes. This
was refined recently by Sprangers et al., who found that all
three monocyte subtypes differentiate equally well on plastic,
but that only the classical and intermediate ones form resorbing
osteoclasts on bone (6). On bone slices, non-classical monocytes
hardly differentiated and no resorption was observed. For some
of the inflammatory bone loss diseases, however, several studies
indicate that likely the CD16+ monocytes are important for
osteoclast formation. A skew distribution compared to healthy
controls was demonstrated for several inflammatory bone loss
diseases. It was demonstrated for multiple myeloma, that
CD14+CD16+ monocytes are predominant in active disease
FIGURE 2 | Common denominators for osteoclast formation in diseases with
inflammatory bone loss. 1. Serum of patients with inflammatory bone loss
diseases contains more osteoclastogenesis stimulating factors such as
RANKL, TNF-α, IL-7, and M-CSF. 2. These serum factors prime OCp present
in peripheral blood. These OCp are skewed toward more CD14+CD16+ cells.
3. T-cells from patients with inflammatory bone diseases express more IL-17,
RANKL, and TNF-α. When these different OCp and T-cells—both of them
different from controls—are added together, more osteoclasts are formed that
are more active in bone resorption.
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compared to smoldering disease. These cells gave rise to larger
osteoclasts (70). Also in kidney disease, more CD14+CD16+
monocytes were found in peripheral blood, and exclusively more
“inflammatory” monocytes expressed RANKL, providing the
possibility for auto-stimulation (39). Patients with Gaucher’s
disease (41) and patients with phenylketonuria (43) have more
CD14+CD16+ monocytes in peripheral blood than matched
controls. All the above studies are association studies, where
a higher percentage of CD14+CD16+ in blood of patients is
associated with increased osteoclast formation. To prove that
these cells indeed give rise to more osteoclasts, Chiu et al., have
sorted the three subtypes of OCp from psoriatic arthritis patients
and healthy controls (71). Interestingly, the CD16+ monocytes
from controls gave rise to low levels of osteoclasts, whereas the
CD16+ monocytes from patients gave rise to high numbers of
osteoclasts. This suggests that apart from the common distinction
of OCp with the CD14 and CD16 markers, other features have
been acquired by psoriatic arthritis patients, making them more
equipped to differentiate into osteoclasts. An experiment with
healthy control OCps confirmed the relative inertness of CD16+
monocytes in healthy controls. When adding increasing numbers
of CD16+ monocytes to a constant number of CD14+CD16–
monocytes in an osteoclastogenesis experiment, there was no
increase in osteoclast numbers, suggesting that under these
conditions, only the CD14+CD16– monocytes contributed to
the formation of a syncytium (72).
Concluding Remarks on the Common
Denominators for Increased Osteoclast
Formation in Patients With Inflammation
Related Bone Loss
In summary, this core collection of studies with well-matched
bone-loss patient—healthy controls, unequivocally shows an
increased osteoclast formation and activity in patients with
inflammatory bone loss. In search for the conditions that give
rise to this, several factors that are shared between diseases
can be identified. First of all, the serum that surrounds
OCp in the circulation is beneficiary for the differentiation
of OCp. Second, T-cells that secrete TNF-α and RANKL are
present in the circulation of patients. In light of the fact that
inflammatory bone loss diseases may occur simultaneously,
anti-TNF-α treatment could benefit more than one disease,
as was shown for instance in rheumatoid arthritis patients
receiving anti-TNF-α medication infliximab, who had lower
periodontal indices. Finally, the patient blood may contain
more OCp and differently primed OCp, probably containing the
CD14+CD16+ phenotype rather than CD14+CD16–. On top of
that, either disease specific or a general immunological stimulus
has given the OCp from bone loss patients a profile to facilitate
enhance osteoclast formation (Figure 2). Future research will
likely uncover the barcodes of the OCps in the various
inflammatory diseases associated with bone loss. This knowledge
of the biological mechanisms underlying the alterations of
monocytes and osteoclasts will likely reveal future therapeutic
targets that will specifically target the immune system-steered
osteoclast formation.
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